Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model

Zunino,Susan  J.; Storms,David  H.; Newman,John  W.; Pedersen,Theresa  L.; Keen,Carl  L.; Ducore,Jonathan   M.

doi:10.3892/ijo.2011.1316

Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model

Authors:
- Susan J. Zunino
- David H. Storms
- John W. Newman
- Theresa L. Pedersen
- Carl L. Keen
- Jonathan M. Ducore
View Affiliations

Affiliations: Western Human Nutrition Research Center, 430 West Health Sciences Drive, University of California, Davis, CA 95616, USA
Published online on: December 22, 2011 https://doi.org/10.3892/ijo.2011.1316
Pages: 1277-1284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The efficacy of resveratrol as a preventive agent against the growth of t(4;11) acute lymphoblastic leukemia (ALL) was evaluated in NOD.CB17-Prkdcscid/J mice engrafted with the human t(4;11) ALL SEM cell line. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with resveratrol (10 mg/kg body weight) dissolved in dimethylsulfoxide (DMSO) or DMSO alone (control) every other day, or vincristine (0.5 mg/kg body weight) 3 times per week for 4 weeks (n=16 per group). Comparisons of the percent of human leukemia cells in blood and survival curves showed resveratrol did not inhibit progression of the disease. Liquid chromatography-tandem mass spectrometry analyses of mouse sera showed resveratrol was rapidly metabolized to glucuronidated and sulfated forms 1 h post-injection, with low to no resveratrol or metabolites observed in sera by 24-48 h. These data indicate that in contrast to findings in in vitro models, parenterally administered resveratrol does not have potential as a preventive agent against high risk t(4;11) ALL.

View Figures

View References

1	Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24:2783–2840. 2004.
2	Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218–220. 1997.
3	Banerjee S, Bueso-Ramos C and Aggarwal BB: Suppression of 7,12- dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κB, cyclooxygenase 2, and matrix metalloproteinase 9. Cancer Res. 62:4945–4954. 2002.
4	Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, Ding Y, Kaganoi J, Hashimoto Y and Imamura M: Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis. 23:1531–1536. 2002.
5	Lee EO, Lee HJ, Hwang HS, Ahn KS, Chae C, Kang KS, Lu J and Kim SH: Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis. 27:2059–2069. 2006.
6	Liu HS, Pan CE, Yang W and Liu XM: Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol. 9:1474–1476. 2003.
7	Tessitore L, Davit A, Sarotto I and Caderni G: Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis. 21:1619–1622. 2000.
8	Chen Y, Tseng S-H, Lai H-S and Chen W-J: Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery. 136:57–66. 2004.
9	Colin D, Limagne E, Jeanningros S, Jacquel A, Lizard G, Athias A, Gambert P, Hichami A, Latruffe N, Solary E and Delmas D: Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells. Cancer Prev Res. 4:1095–1106. 2011.
10	Li G, He S, Chang L, Lu H, Zhang H and Chiu J: GADD45α and annexin A1 are involved in the apoptosis of HL-60 induced by resveratrol. Phytomedicine. 18:704–709. 2011.
11	Kartal M, Saydam G, Sahin F and Baran Y: Resveratrol triggers apoptosis through ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr Cancer. 63:637–644. 2011.
12	Faderl S, Kantarjian HM, Talpaz M and Estrov Z: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 91:3995–4019. 1998.
13	Greaves MF and Wiemels J: Origins of chromosome translocations in childhood leukaemia. Nat Rev. 3:1–11. 2003.
14	Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, Trautmann U, Hansen-Hagge TE, Bartram CR, Fey GH, Stehr K and Beck J: The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Hemotol. 86:275–283. 1994.
15	Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC and Kersey JH: Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 65:21–31. 1985.
16	Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I, Griffin C, Emanuel B, Finan J and Nowell P: Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood. 70:192–199. 1987.
17	Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, Haber M, Norris MD, Marshall GM and Rice AM: The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood. 99:4100–4108. 2002.
18	Liem NLM, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, MacKenzie KL and Lock RB: Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 103:3905–3914. 2004.
19	Shultz LD, Ishikawa F and Greiner DL: Humanized mice in translational biomedical research. Nat Rev Immunol. 7:118–130. 2007.
20	Lee EM, Bachman PS and Lock RB: Xenograft models for the preclinical evaluation of new therapies in acute leukemia. Leuk Lymphoma. 48:659–668. 2007.
21	Borgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, Nurnberg P and Henze G: Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol. 17:635–650. 2000.
22	Dörrie J, Gerauer H, Wachter Y and Zunino SJ: Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 61:4731–4739. 2001.
23	Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM and Gaynon PS: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 338:1663–1671. 1998.
24	Center for Veterinary Medicine, Food and Drug Administration. Guidance for industry validation of analytical procedures for type C medicated feeds #135. United States Department of Health and Human Services; pp. 1–14. 2005, http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052530.pdf.
25	Zunino SJ, Storms DH and Ducore JM: Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Cancer Lett. 296:49–54. 2010.
26	Lee M-H, Choi BY, Kundu JK, Shin YK, Na H-K and Surh Y-J: Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res. 69:7449–7458. 2009.
27	Bai Y, Mao Q-Q, Qin J, Zheng X-Y, Wang Y-B, Yang K, Shen H-F and Xie L-P: Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 101:488–493. 2010.
28	El-Mowafy AM, El-Mesery ME, Salem HA, Al-Gayyar MM and Darweish MM: Prominent chemopreventive and chemoenhancing effects for resveratrol: unraveling molecular targets and the role of C-reactive protein. Chemotherapy. 56:60–65. 2010.
29	Kenealey JD, Subramanian L, Van Ginkel PR, Darjatmoko S, Lindstrom MJ, Somoza V, Ghosh SK, Song Z, Hsung RP, Kwon GS, Eliceiri KW, Albert DM and Polans AS: Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells. J Agric Food Chem. 59:4979–4986. 2011.
30	Lanzkowsky P, Shende A, Aral I and Saluja G: Organ irradiation and combination chemotherapy in treatment of acute lymphocytic leukaemia in children. Arch Dis Child. 50:685–690. 1975.
31	Crowell JA, Korytko PJ, Morrissey RL, Booth TD and Levine BS: Resveratrol-associated renal toxicity. Toxicol Sci. 82:614–619. 2004.
32	Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, Barthe N, Rosenbaum J and Merillon J-M: Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 72:2219–2233. 2003.
33	Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG and van Breeman RB: Human, rat, and mouse metabolism of resveratrol. Pharm Res. 19:1907–1914. 2002.
34	Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY and Sun AY: Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 958:439–447. 2002.
35	Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD and Mesecar AD: Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J. 429:273–282. 2010.
36	Hoshino J, Park E-J, Kondratyuk TP, Marler L, Pezzuto JM, van Breemen RB, Mo S, Li Y and Cushman M: Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 53:5033–5043. 2010.
37	Mikulski D and Molski M: Quantitative structure-antioxidant activity relationship of trans-resveratrol oligomers, trans-4,40-dihydroxystilbene dimer, trans-resveratrol-3-O-glucuronide, glucosides: trans-piceid, cis-piceid, trans-astringin and trans-resveratrol-40-O-b-D-glucopyranoside. Eur J Med Chem. 45:2366–2380. 2010.
38	Miksits M, Wlcek K, Svoboda M, Kunert O, Haslinger E, Thalhammer T, Szekeres T and Jäger W: Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 75:1227–1230. 2009.
39	Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies SD and Sondel PM: Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy. Int Immunopharmacol. 11:1877–1886. 2011.
40	Niu XF, Liu BQ, Du ZX, Gao YY, Li C, Li N, Guan Y and Wang HQ: Resveratrol protects leukemic cells against cytotoxicity induced by proteasome inhibitors via induction of FOXO1 and p27Kip1. BMC Cancer. 11:992011.open access. [21418583]
41	Fukui M, Yamabe N and Zhu BT: Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer. 46:1882–1891. 2010.